Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 101 - 110 of 134

Selected Filters:
22 November 2022

A Qualitative Exploration of New and Existing HIV PrEP Modalities Among Men Who Have Sex with Men in Philadelphia

This article from Open Forum Infectious Diseases explores the treatment characteristics that may influence the willingness and uptake of long-acting injectable PrEP as opposed to the daily pills among a racially diverse sample of gay and bisexual men who have sex with men in Philadelphia, Pennsylvania, USA.

Demand Creation/Marketing, Service Delivery

External Link
18 November 2022

Transgender Women in HPTN 083: An evaluation of safety, efficacy, and gender affirming hormonal therapy interactions with long-acting cabotegravir

This poster from AIDS 2022 presents an analysis of results from the HPTN 083 study, looking at the impact of feminizing gender affirming hormones on cabotegravir (CAB) for PrEP pharmacokinetics.

Research

Document
10 November 2022

Relative Cost-effectiveness of Long-acting Injectable Cabotegravir versus Oral Pre-exposure Prophylaxis in South Africa based on the HPTN 083 and HPTN 084 Trials: A modelled economic evaluation and threshold analysis

This article from The Lancet HIV estimates the incremental cost-effectiveness of long-acting injectable cabotegravir (CAB for PrEP) compared with tenofovir disoproxil fumarate and emtricitabine (TDF/FTC oral PrEP) in South Africa, using methods standard to government planning, and determines the threshold price at which CAB for PrEP is as cost-effective as TDF/FTC oral PrEP.

Financing & Costing, Research

External Link
3 November 2022

ICAP Grand Rounds Webinar- Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls

Recording / Slides Two recent landmark HIV Prevention Trials Network (HPTN) studies demonstrated the efficacy of long-acting, injectable cabotegravir (CAB) as PrEP against HIV. These studies showed that CAB for PrEP injected once every eight weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for PrEP among cisgender men and transgender women who have sex with…

Research

Event
14 October 2022

Long-acting injectable cabotegravir for HIV prevention: WHO guidelines, implementation considerations, and project examples

Recording During this 90-minute webinar, speakers will provide an overview of the new WHO guidelines on CAB for PrEP, discuss implementation issues specifically relating to HIV testing and drug resistance, and highlight examples of planned implementation projects in sub-Saharan Africa and Asia. This webinar is presented by the Global PrEP Network, a WHO-led forum designed…

Research, Normative Guidance/Policies, Testing

Event
4 October 2022

Acceptability of Injectable Pre-exposure Prophylaxis among People who Inject Drugs in Three Urban U.S. Settings

This article from BMC Infectious Diseases examines acceptability of injectable PrEP amongst people who inject drugs in the US.

Research

External Link
4 October 2022

Long-Acting Injectable Cabotegravir for HIV Prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance?

This article from The Science of Prevention summarizes what is known about cabotegravir (CAB) pharmacokinetics, activity, and emergence of resistance from in vitro, macaque and clinical studies, and evaluates the risk of resistance from CAB for PrEP with on-time injections and after CAB for PrEP discontinuation.

Monitoring & Evaluation, Research, Testing

External Link
31 August 2022

Coordinating Implementation Science for CAB for PrEP: Focus on Delivery Models

This second meeting of the BioPIC implementation science series focused on how cabotegravir (CAB) for PrEP can be integrated into existing community, pharmacy and facility-based delivery for HIV prevention.

Research

Document
19 August 2022

Implementation Science Questions for CAB for PrEP

This document outlines the key evidence gaps around cabotegravir (CAB) for PrEP that should be addressed when designing implementation research.

Research

Document
16 August 2022

Background Resources on Cabotegravir for PrEP

This document, produced by the MOSAIC consortium, provides a list of key resources on research and evidence for cabotegravir (CAB) for PrEP.

Research

Document